Syndax announces CFO transition - Aaron A. Ondrey appointed Chief Financial Officer. - Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions. Current Chief Financial Officer Keith A. Goldan has decided to retire from the position and will remain with the Company through the end of 2026 to support the transition. Mr. Goldan led Syndax's financial and capital strategy during an important period in the Company's history. He played a key role in the successful launches of Revuforj and Niktimvo and in initiatives that strengthened the Company's pipeline and innovative R&D platform. "On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement," said Michael A. Metzger, Chief Executive Officer of Syndax. "Keith was integral to Syndax's transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success." Mr. Metzger continued, "We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value." "I am thrilled to join Syndax at such a pivotal moment in the Company's evolution," said Aaron A. Ondrey. "Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company's leadership position and its strong financial foundation." "It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team," said Keith A. Goldan, Chief Financial Officer of Syndax. "I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future." Mr. Ondrey brings extensive leadership and financial experience across both pre-commercial and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Beren Therapeutics, where he oversaw finance, investor relations, and manufacturing operations. Prior to joining Beren Therapeutics, Mr. Ondrey served as Chief Financial Officer of Rocket Pharmaceuticals, where he led the company's financial strategy as it prepared for its transition to a commercial-stage organization. Before Rocket Pharmaceuticals, he was Chief Financial Officer and Senior Vice President at Mirati Therapeutics, where he supported the commercialization of KRAZATI(R) and played a key role in the company's acquisition by Bristol Myers Squibb in January 2024. Earlier in his career, Mr. Ondrey held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals, building extensive experience in corporate finance, strategic planning, commercialization, and operational execution. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj(R)(revumenib), an FDA-approved menin inhibitor, and Niktimvo(TM)(axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo's commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827

Rocket Pharmaceuticals has secured a credit facility of up to $150 million from Hercules Capital to support its pivotal Phase 2 study of RP-A501 for Danon disease and advance its cardiovascular pipeline. The commercial-stage biotechnology company received $35 million at closing and may draw an additional $35 million during specified periods. A further $30 million becomes available upon achieving a specified Danon clinical milestone, whilst an additional $50 million is subject to Hercules' investment committee approval. The facility has an initial 30-month interest-only period and 48-month maturity, with possible extensions. As of 30 June 2026, Rocket had $283.7 million in cash and investments. Combined with the initial facility drawdown, the company expects to fund operations into the third quarter of 2028, with potential extension into 2029 through additional borrowings.

Lexeo Therapeutics completes strategic acquisition: deal analysis and market outlook. Wednesday, September 30, 2026 Lexeo Therapeutics has finalized a transformative acquisition, marking a pivotal expansion in its clinical-stage genetic medicine pipeline. Detailed in a recent SEC filing, this strategic move aims to strengthen the company's competitive moat and drive accelerated pipeline development. Here is its in-depth analysis of the transaction structure, market implications, and future outlook for LXEO. Lexeo Therapeutics' (NASDAQ: LXEO) formal disclosure of a completed acquisition under Item 2.01 of Form 8-K signals a decisive step in the company's targeted expansion strategy. Operating at the complex intersection of cardiovascular genetics and central nervous system (CNS) therapeutics, the clinical-stage biotechnology firm is navigating a macro environment characterized by rigorous capital discipline and a flight to high-conviction clinical assets. By executing this transaction, Lexeo not only expands its technical or clinical footprint but also underscores a broader shift among mid-cap biotech operators toward strategic consolidation as a means of pipeline de-risking and platform enhancement. Strategic rationale: targeted expansion in adeno-associated virus (AAV) biology. The strategic core of this transaction aligns directly with Lexeo's overarching mandate: advancing proprietary adeno-associated virus (AAV) gene therapies for genetically defined diseases with substantial unmet medical need. Historically anchored by lead programs - including LX2006 for Friedreich's ataxia (FA) cardiomyopathy and LX1001 for APOE4-associated Alzheimer's disease - Lexeo has balanced high-prevalence neurological targets with high-probability monogenic rare diseases. This acquisition serves several strategic imperatives: * Consolidation of Proprietary Technology: The integration of supplementary intellectual property or complementary pipeline assets bolsters Lexeo's competitive moat in capsid engineering and vector design, an increasingly vital differentiator against both legacy gene therapy developers and emerging non-viral delivery platforms. * Pipeline Synergies: By acquiring complementary clinical or preclinical technology, Lexeo effectively compresses development timelines, bypassing years of de novo discovery work to augment its core competencies in rare cardiovascular disease. * Manufacturing and Translatability: Scale and vector yield remain persistent bottlenecks across the AAV landscape. Incorporating platform improvements or upstream manufacturing efficiencies allows the company to reduce cost-of-goods-sold (COGS) expectations ahead of late-stage pivotal trials. In an AAV sector historically plagued by safety and delivery constraints, acquiring specialized vector biology or targeted preclinical programs offers Lexeo an avenue to accelerate translational milestones while preserving its fundamental clinical focus. Deal architecture and capital discipline. While full financial schedules in early 8-K filings often omit localized line-item values, the transaction's architecture reflects current norms within biotechnology dealmaking. Clinical-stage biotechs currently trade under the scrutiny of an unforgiving cost-of-capital environment, where outright cash exits are rare. Instead, recent corporate acquisitions across the sector have increasingly prioritized deferred consideration, back-loaded milestone payments, and equity-based compensation to align incoming stakeholders with long-term enterprise value creation. From a balance sheet perspective, Lexeo's ability to close the transaction without triggering immediate, punitive dilution is critical. The market has heavily penalized gene therapy biotechs that overextend their cash runways on high-beta platform acquisitions. By leveraging structured consideration - typically split between upfront equity, near-term regulatory milestones, and commercial earn-outs - Lexeo maintains operational flexibility for its ongoing Phase 1/2 reads. The transaction demonstrates disciplined corporate development: acquiring strategic capabilities while keeping the primary cash burn directed toward clinical execution. Competitive repositioning and market implications. The broader implications for the genetic medicine ecosystem are tangible. Over the past twenty-four months, mid-cap biopharmas have been compelled to transition away from horizontal exploration - amassing sprawling discovery engines - toward vertical integration that solves specific clinical or delivery vulnerabilities. * Re-evaluating the Rare Disease Arbitrage: By deepening its hold on rare cardiac and neurological genetics, Lexeo strengthens its positioning against established peers such as Rocket Pharmaceuticals and Sarepta Therapeutics. As the regulatory frameworks at the FDA continue to evolve favorably toward biological surrogates in monogenic diseases, owning robust, turnkey assets becomes an acute strategic advantage. * Big Pharma In-Licensing Dynamics: Large pharmaceutical players face historic patent cliffs toward the end of the decade, particularly in oncology and immunology, driving renewed interest in rare genetic platforms that demonstrate clean safety profiles and clear biomarker engagement. Transactions of this nature position Lexeo not just as a standalone commercial operator, but as an increasingly attractive, coherent bolt-on candidate for global pharmaceutical companies seeking differentiated rare-disease platforms. * Sector-Wide Consolidation Pressures: The completion of this deal mirrors a continuing trend across the biotech landscape. Smaller discovery shops lacking the capital runway to reach the clinic are increasingly receptive to being rolled up by better-capitalized peers with access to public market liquidity. Strategic outlook: execution on clinical inflections. The integration of the acquired assets will be measured directly against Lexeo's upcoming clinical milestones. For investors, the primary scrutiny will center on operational throughput: how seamlessly the newly incorporated technology or pipeline targets interface with Lexeo's current development framework, and whether the integration introduces unexpected regulatory complexity or cash burn. If management effectively harmonizes this asset within its existing infrastructure, Lexeo stands to capture enhanced programmatic optionality. With key data readouts looming across its cardiac and CNS pipelines, the company's enhanced technical foundation could prove pivotal in driving sustainable value creation, establishing a stronger foundation for clinical progression, institutional support, and long-term strategic flexibility. Ready to analyze your next deal? Upload your CIM for instant AI-powered analysis - financial extraction, risk assessment, and valuation in minutes. Analyze your own CIM. Upload a CIM and get financials, risks, and valuation in seconds.